From seed to win.
Content
Content
Team
Team
Companies
Companies
About
About
Focus Areas
Focus Areas
Bio
Gaming
Generative AI
Proptech
Space
Fintech
Marketplaces
Crypto
Silicon Valley
Israel
Europe
LatAm
Products
Products
Signal
Brieflink
NFX Masterclass
ChatNFX
Get our weekly newsletter that 278K+ startup teams read
Subscribe
Bio
26
Focus Areas
All Focus Areas
Bio
· 26
Gaming
· 6
Generative AI
· 30
PropTech
· 5
Space
· 3
Fintech
· 5
Marketplaces
· 25
Crypto
· 20
Silicon Valley
· 6
Israel
· 10
Europe
· 4
LatAm
· 4
By Author
Anna Piñol
Morgan Beller
Omri Amirav-Drory, Ph.D.
Pete Flint
Gigi Levy-Weiss
James Currier
Topics
Network Effects
· 34
Fundraising
· 26
Growth
· 112
Leadership
· 54
Investment Memos
· 59
Psychology
· 48
Announcements
· 25
By Type
All NFX Content
· 394
Videos
· 37
Podcasts
· 92
Essays
· 165
Bio · 26
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
Why Great Bioplatforms Will Always Win
The Race to 150
The Business Case for Longevity
A Scientific Approach To Your Company (And Your Life)
What I Wish I Knew as a Scientist-Founder
A Scientific Approach to VC
The Future of Longevity: The Battle Against Human Aging (An NFX Documentary)
The NFX Bio Guide to JPM Success
Why NFX Invested in Mana Bio: The TechBio Platform Using AI for Better Drug Delivery
The Future of Longevity: Keeping Healthy People Healthy
The 3 Waves of AI in Bio
Maximizing TechBio Deal Potential: Platform vs. Asset Deals
Deal or Die: Your 3-Part Guide to Business Development in TechBio
Tech Founders, Don’t Be Afraid of Bio
What Doesn’t Kill You, Mutates And Tries Again
From Sick Care to Health Care: Why We Need Longevity Startups
How to Prove Your TechBio Platform at Seed Stage
Why NFX Invested in Centivax: The TechBio Platform Developing Universal Vaccines
Academia or Startup? A Decision Matrix for Future Scientist-Founders
The Golden Ratio: Navigating East Coast v. West Coast in TechBio Investing
From Biotech to TechBio
Launching NFX Bio and The Rise of the Scientist Founder
Mammoth Expands Bio-Platform Network Effects to Gene-Editing
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
Why Great Bioplatforms Will Always Win
The Race to 150
The Business Case for Longevity
A Scientific Approach To Your Company (And Your Life)
What I Wish I Knew as a Scientist-Founder
A Scientific Approach to VC
The Future of Longevity: The Battle Against Human Aging (An NFX Documentary)
The NFX Bio Guide to JPM Success
Why NFX Invested in Mana Bio: The TechBio Platform Using AI for Better Drug Delivery
The Future of Longevity: Keeping Healthy People Healthy
The 3 Waves of AI in Bio
Maximizing TechBio Deal Potential: Platform vs. Asset Deals
Deal or Die: Your 3-Part Guide to Business Development in TechBio
Tech Founders, Don’t Be Afraid of Bio
What Doesn’t Kill You, Mutates And Tries Again
From Sick Care to Health Care: Why We Need Longevity Startups
How to Prove Your TechBio Platform at Seed Stage
Why NFX Invested in Centivax: The TechBio Platform Developing Universal Vaccines
Academia or Startup? A Decision Matrix for Future Scientist-Founders
The Golden Ratio: Navigating East Coast v. West Coast in TechBio Investing
From Biotech to TechBio
Launching NFX Bio and The Rise of the Scientist Founder
Mammoth Expands Bio-Platform Network Effects to Gene-Editing
Load More Content
Subscribe for more Bio insights
Get our weekly newsletter that 278K+ startup teams read
Subscribe
Try ChatNFX